Make new contributions to breakthroughs in core biopharmaceutical technologies

In the report of the 20th National Congress of the Communist Party of China, the General Secretary of the People's Republic of China specifically mentioned the breakthrough of key core technologies such as biopharmaceuticals, entering the ranks of innovative countries, and made important statements such as adhering to the principle that science and technology are the first productive force, talent is the first resource, innovation is the first driving force, and accelerating the realization of high-level technological self-reliance and self-improvement. As a member of the biopharmaceutical industry, I feel honored and more confident. We will definitely make new contributions to the biopharmaceutical industry Recently, Guo Yanchao, Chairman of Juxin Biotechnology Co., Ltd. (referred to as Juxin Biotechnology) in Dancheng County, Zhoukou National Agricultural High tech Zone, Henan Province, was excited to learn and implement the spirit of the 20th National Congress.

In recent years, the importance of scientific research and innovation in the high-quality development process of Juxin Biotechnology has been continuously highlighted, and a batch of significant scientific and technological achievements with iconic significance have been produced in basic cutting-edge fields and key technologies. The company undertakes two national "863 Program" projects, and is the only enterprise producing abacavir, an anti AIDS drug in China, accounting for 100% of the national market; The intermediate product diltiazem hydrochloride produced for the treatment of cardiovascular and cerebrovascular diseases accounts for 100% of the national market share; ACC007 has completely independent intellectual property rights, with a national market share of 100%; The core product of the active pharmaceutical ingredient (veterinary), Benxing Cloxacillin, is the only product in China that has passed GMP certification and has an approval number, with a market share of 100%; We have one major science and technology project in Henan Province, one major science and technology project in Zhoukou City, and one demonstration project for technological transformation in Zhoukou City; At present, we have 12 invention patents and 37 utility model patents. In 2022, we have applied for 10 new patents, including 3 invention patents; In the past three years, 22 scientific and technological achievements have been transformed, all of which were self invested and implemented.

Guo Yanchao introduced that as the main battlefield for promoting breakthroughs in the biopharmaceutical industry and building a billion dollar industrial cluster, Juxin Biotechnology continues to make efforts in research and development innovation, talent cultivation, market expansion, and other aspects, driving the further aggregation of the biopharmaceutical industry chain, expanding the industrial scale, and achieving high-quality and rapid development.

Guo Yanchao said that next, Juxin Biotechnology will take the spirit of the 20th National Congress of the Communist Party of China as a guide, and take the intelligent automation transformation of production workshops, industrialization of scientific research achievements, and construction of pharmaceutical industry parks as the main focus to create high-quality development engines. The focus will be on building 8 new workshops (2 national standard GMP workshops, 6 pharmaceutical raw material production workshops), 9 classification standard warehouses, 1 exhibition hall, 1 multifunctional laboratory, and related supporting facilities; Two GMP workshops produce Chinese herbal medicine, formula granules, wet processing of decoction pieces, and a series of Chinese herbal health products; The two products currently in the pilot stage of research and development, Qingcamycin and Nongkang 702, are striving to enter clinical practice within 3-5 years and are expected to fill the gap in the new generation of antibiotics.

"We are firmly guided by national strategic needs, focusing on original and leading technological breakthroughs, and resolutely winning the battle for key core technologies. Focusing on the 'primary task', we will muster up our energy, sprint for the fourth quarter, learn and implement the spirit of the 20th National Congress of the Communist Party of China through practical actions, firmly establish the concept of 'project is king', seize the strategic opportunity of building biopharmaceutical industrial parks at the provincial and municipal levels, accelerate the development process of biopharmaceuticals, continuously expand new drug reserve resources, build a complete tiered biopharmaceutical product cluster, comprehensively improve the modernization level of the pharmaceutical industry, better meet the diversified and multi-level health needs of the people, and make new contributions to the breakthrough of biopharmaceutical core technology." Guo Yanchao said.